Neurotech market: $2.36B raised across 30 deals Q1 2025 — Q1 2026, BCI captures 75% of all capital
Summary
Market intelligence from New Market Pitch tracked $2.36 billion in neurotechnology funding across 30 publicly disclosed rounds from Q1 2025 through Q1 2026. BCI startups captured approximately 75% of all funding ($1.77B across 11 deals). Q1 2026 alone reached $976M — 577% higher than Q1 2025's $144M. Q2 2025 was dominated by Neuralink's $650M Series E (86% of that quarter). Only 5 investors appeared in more than one deal, indicating a still-fragmented investor base. Khosla Ventures was the most active, participating in Somnee, Synchron, and Science Corporation.
Why it matters
Five quarters of neurotechnology funding data showing $2.36B total with accelerating momentum through Q1 2026 is the most comprehensive market sizing dataset for the sector. The 75% BCI share reflects investor concentration on the highest-profile technology, while neuromodulation's 12-deal count across the widest indication range reflects broader commercial maturity.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial